Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL
Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL
Not yet recruiting · NCT06573138 · Registry updated 2024-08-27Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL | Lymphoma, Extranodal NK-T-Cell, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, lymphoma, neoplasm | Not yet recruiting | Phase 2 | 2024-08-27 | NCT06573138 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Ruijin Hospital | 454 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||